Abstract
Systemic inflammation score (SIS) is one of the prognostic indicators using lymphocyte-to-monocyte ratio (LMR) and serum Alb level, and has been reported in various solid tumors recently. However, its significance in patients treated with chemoradiotherapy (CRT) for esophageal squamous cell carcinoma (ESCC) remains unclear. The aim of the present study is to investigate the clinical usefulness of SIS in patients who underwent CRT for ESCC.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
